logo
episode-header-image
May 2023
28m 12s

Narcos and avocados: Mexico’s diversifyi...

The Economist
About this episode

In attempts to amass more wealth, these organisations are dabbling in newer narcotics and even taking on the mining sector. The result is taking a toll on the country’s economy. Can a 100-year-old discovery solve the problem of antibiotic resistance? And we celebrate the anniversary of William Shakespeare’s first folio.


For full access to print, digital and audio editions of The Economist, try a free 30-day digital subscription by going to www.economist.com/intelligenceoffer



Hosted on Acast. See acast.com/privacy for more information.

Up next
Yesterday
At your services: Britain’s economic bright spot
Growth is abysmal; wages are low. But seen from the outside, Britain is a great place to contract services and buy bargain-basement bonds. We explore the opportunities amid the challenges. After months of reporting, our correspondent shares what he learned about Austin Tice, a mi ... Show More
23m 14s
Jul 10
Migration roots: the broken asylum system
Immigration is a political lightning rod in part because the ageing global asylum pact is no longer fit for purpose. We examine how best to update it. As paycheques for top-notch AI researchers go stratospheric, demand for rank-and-file coders is quickly cooling. And what a gimmi ... Show More
21m 49s
Jul 9
Sprawl of duty: Trump’s tariff drama
Once again President Donald Trump extended the deadline for spine-stiffening tariffs to go into effect on trading partners. We look at the effects of all the uncertainty. Brazil once dominated the world of football; we ask where it went wrong and assess the route to a comeback. A ... Show More
21m 53s
Recommended Episodes
May 2023
Narcos and avocados: Mexico’s diversifying drug cartels
In attempts to amass more wealth, these organisations are dabbling in newer narcotics and even taking on the mining sector. The result is taking a toll on the country’s economy. Can a 100-year-old discovery solve the problem of antibiotic resistance? And we celebrate the annivers ... Show More
28m 12s
Mar 2022
Babbage: The fountain of youth
Billions of dollars are being pumped into technologies that hope to reduce the effects of ageing. Host Alok Jha explores the latest research in the field—from regenerating organs to rejuvenating cells—and whether these efforts could help to conquer debilitating human diseases. Is ... Show More
39m 52s
Mar 2022
Babbage: The fountain of youth
Billions of dollars are being pumped into technologies that hope to reduce the effects of ageing. Host Alok Jha explores the latest research in the field—from regenerating organs to rejuvenating cells—and whether these efforts could help to conquer debilitating human diseases. Is ... Show More
39m 52s
Oct 2022
Editor’s Picks: October 10th 2022
A selection of three essential articles read aloud from the latest issue of The Economist. This week, the outlook for the world economy, how worried you should be about Elon Musk’s superpowers (12:50), and a study allays fears that covid vaccines harm menstrual cycles (16:50). Pl ... Show More
23m 8s
Oct 2022
Editor’s Picks: October 10th 2022
A selection of three essential articles read aloud from the latest issue of The Economist. This week, the outlook for the world economy, how worried you should be about Elon Musk’s superpowers (12:50), and a study allays fears that covid vaccines harm menstrual cycles (16:50). Pl ... Show More
23m 8s
Jun 2022
Editor’s Picks: June 13th 2022
A selection of three essential articles read aloud from the latest issue of The Economist. This week, why foundation models are artificial intelligence’s new frontier, the stagnation nation: a chronic British disease (10:30), and why visiting the scenes of stories is an act of im ... Show More
24 m
Apr 2024
Money Talks: Why weight-loss drugs will reshape the world
More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs that ... Show More
36m 59s
Dec 2023
The Intelligence: searching for the elixir of life
Scientists are making considerable progress in the race to slow the ageing process of our cells, and in turn, our bodies. But what would living for longer actually mean for the world? How government legislation and impatient consumers are forcing the advertising industry to adapt ... Show More
30m 6s
Oct 2023
Editor’s Picks: October 9th 2023
A selection of three essential articles read aloud from the latest issue of The Economist. This week, are free markets history? Also, why Africans are losing faith in democracy (10:25) and we investigate whether bitcoin originally leaked from an American spy lab. (17:25)  Sign up ... Show More
21m 46s
Mar 2024
The Intelligence: Europe is not so hot on its green parties
Melting ski slopes, floods and droughts are enraging the continent’s citizens, but not quite enough for them to consider voting differently. Our correspondent explains what the electorate is weighing up. The world’s largest maker of glasses is branching out into tech (10:41). And ... Show More
24m 14s